Australia markets open in 9 hours 40 minutes

Immuneering Corporation (IMRX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.3600-0.0200 (-1.45%)
As of 10:20AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 40.92M
Enterprise value -25.98M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)563.62
Price/book (mrq)0.52
Enterprise value/revenue 191.91k
Enterprise value/EBITDA -1.53

Trading information

Stock price history

Beta (5Y monthly) -0.60
52-week change 3-85.59%
S&P500 52-week change 324.60%
52-week high 311.0600
52-week low 31.3000
50-day moving average 31.5251
200-day moving average 34.8940

Share statistics

Avg vol (3-month) 3365.96k
Avg vol (10-day) 3216.37k
Shares outstanding 529.65M
Implied shares outstanding 629.65M
Float 817.41M
% held by insiders 129.15%
% held by institutions 134.88%
Shares short (14 June 2024) 43.69M
Short ratio (14 June 2024) 417.48
Short % of float (14 June 2024) 416.71%
Short % of shares outstanding (14 June 2024) 412.43%
Shares short (prior month 15 May 2024) 43.53M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-37.73%
Return on equity (ttm)-61.38%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -58.69M
Net income avi to common (ttm)-54.18M
Diluted EPS (ttm)-1.8600
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)71.28M
Total cash per share (mrq)2.4
Total debt (mrq)4.38M
Total debt/equity (mrq)5.56%
Current ratio (mrq)14.38
Book value per share (mrq)2.65

Cash flow statement

Operating cash flow (ttm)-50.04M
Levered free cash flow (ttm)-31.72M